CancerNext-Expanded
Use
CancerNext-Expanded is intended to determine if a person has an inherited cancer predisposition condition by analyzing 77 genes associated with increased risk for various cancers such as breast, ovarian, uterine, colorectal, gastric, pancreatic, prostate, melanoma, kidney, central nervous system tumors, and pheochromocytoma/paraganglioma. It's recommended for individuals with suspicious personal or family histories of these cancers. The panel includes certain hematologic malignancy predisposition genes.
Special Instructions
For certain patients, additional genes for pancreatitis risk or with limited evidence of association with cancer predisposition can be included through respective add-ons. Family variant testing is available at no additional cost for blood relatives of patients with a pathogenic or likely pathogenic variant.
Limitations
Variants that are difficult to analyze, such as those in pseudogene regions or not meeting depth of coverage criteria, are confirmed by Sanger sequencing. The MSH3 and PHOX2B polyalanine repeat regions are excluded from analysis, and intronic variants further than 5 base pairs from a splice junction are not reported unless clinically significant. Some genes, like MITF and GREM1, have specific reporting limitations.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
7ml
Minimum Volume
3ml
Container
Purple top (EDTA) tube
Collection Instructions
Standard venipuncture technique.
Storage Instructions
Refrigerate if the delay in transport is expected.
Causes for Rejection
Hemolysis, clotted specimen, wrong anticoagulant.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 7 days |
Other tests from different labs that may be relevant